Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)

被引：0
|
作者：
Sun, M. [1 ]
Spigel, D. R. [2 ]
Lee, Y-J. [3 ]
Yoon, H. [4 ]
Liu, Y. [5 ,6 ]
Ahern, E. [7 ]
Harris, S. [8 ]
Lee, G-W. [9 ,10 ]
Yan, D. [11 ]
Chen, J. [12 ]
Shiah, H-S. [13 ]
Deng, T. [14 ]
Zheng, H. [15 ]
Tan, W. [16 ]
Zhou, Z. [16 ]
Wang, R. [16 ]
Ba, Y. [14 ]
机构：
[1] Shandong First Med Univ, Dept Oncol, Cent Hosp, Jinan, Peoples R China
[2] Sarah Cannon Res Inst, Dept Med Oncol, Nashville, TN USA
[3] Natl Canc Ctr Hosp, Dept Internal Med, Goyang, South Korea
[4] Mayo Clin, Dept Oncol, Rochester, MN USA
[5] Zhengzhou Univ, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
[7] Monash Hlth, Med Oncol, Clayton, Vic, Australia
[8] Bendigo Hlth, Dept Med Oncol, Bendigo, Vic, Australia
[9] Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea
[10] Gyeongsang Natl Univ, Coll Med, Jinju, South Korea
[11] Capital Med Univ, Beijing Luhe Hosp, Dept Oncol, Beijing, Peoples R China
[12] Cent South Univ, Dept Thorac Med Oncol, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China
[13] Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Div Hematol & Oncol, Dept Med, New Taipei, Taiwan
[14] Natl Clin Res Ctr Canc, Dept GI Med Oncol, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[15] BeiGene USA Inc, San Mateo, CA USA
[16] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1445
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1533P
引用
收藏
页码：S862 / S863
页数：2
相关论文
共 32 条
  • [21] RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
    Yoon, H.
    Kato, K.
    Raymond, E.
    Hubner, R.
    Shu, Y.
    Pan, Y.
    Jiang, Y.
    Zhang, J.
    Park, S.
    Kojima, T.
    Lin, C.
    Gotovkin, E.
    Wyrwicz, L.
    Ishihara, R.
    Li, L.
    Tao, A.
    Shi, J.
    Wang, L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S375 - S375
  • [22] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
    Cruz-Correa, M.
    Oh, D-Y.
    Kato, K.
    Tabernero, J.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Cubillo Gracian, A.
    Li, L.
    Xu, Y.
    Sheng, T.
    Yang, S.
    Xu, R-H.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S893 - S894
  • [23] Randomized, global, phase 3 study of tislelizumab (TIS) plus chemotherapy (chemo) versus placebo (PBO) plus chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
    Raymond, Eric
    Hubner, Richard
    Gotovkin, Evgeny
    Wyrwicz, Lucjan
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Pazo-Cid, Roberto
    Xu, Jianming
    Kato, Ken
    Tao, Aiyang
    Wang, Lei
    Peng, Yanyan
    Li, Liyun
    Yoon, Harry H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 340 - 340
  • [24] GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
    Li, J.
    Chen, Z.
    Bai, Y.
    Liu, B.
    Li, Q.
    Zhou, J.
    Zhang, J.
    Deng, T.
    Zhou, F.
    Gao, S.
    Yang, S.
    Ye, F.
    Chen, L.
    Bai, W.
    Yin, X.
    Xu, Y.
    Hu, J.
    Ni, J.
    Wang, B.
    Yang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S181 - S182
  • [25] Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
    Lee, K-W.
    Bai, L-Y.
    Jung, M.
    Ying, J.
    Im, Y-H.
    Oh, D-Y.
    Cho, J. Y.
    Oh, S. C.
    Chao, Y.
    Zhou, P.
    Bao, Y.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S855 - S856
  • [26] Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Kim, S-B.
    Keam, B.
    Shin, S.
    Chae, Y. S.
    Seo, S.
    Park, K.
    Kim, T. M.
    Park, L. C.
    Hong, S-B.
    Lim, E.
    Lee, S.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S667 - S668
  • [27] SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) plus atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).
    Hsu, Chih-Hung
    Lu, Zhihao
    Gao, Shegan
    Wang, Jun-Ye
    Sun, Jong-Mu
    Liu, Tianshu
    Fan, Qingxia
    Cai, Jun
    Ge, Feijiao
    Li, Sijing
    Zhang, Li
    Cha, Edward
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 245 - 245
  • [28] BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations plus /- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
    He, J.
    Zhang, P.
    Liu, H.
    Liang, W.
    Yu, W.
    Shi, J.
    Wei, B.
    Zheng, W.
    Shen, Z.
    Wu, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1652 - S1653
  • [29] Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs) plus /- chemotherapy (CT) and prebiotic inulin in the PRINCESS study
    Galizia, D.
    Minei, S.
    Abbona, A.
    Paccagnella, M.
    Piccinno, G.
    Polidori, A.
    De Zarlo, L.
    Albini, M.
    Rizzo, A.
    Campanella, D.
    Cappello, G.
    Enrico, F.
    Bondi, S.
    Segata, N.
    Gregorc, V.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S560 - S560
  • [30] Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Kim, S-B.
    Keam, B.
    Shin, S-H.
    Chae, Y.
    Seo, S.
    Park, K.
    Kim, T. M.
    Park, L. C.
    Hong, S-B.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S797 - S797
1234